(Q38415424)

English

Efficacy and safety of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in diabetic nephropathy: a meta-analysis

scientific article published on 11 April 2015

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

0 references

1 reference

Europe PubMed Central

Efficacy and safety of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in diabetic nephropathy: a meta-analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

1 reference

based on heuristic

inferred from title

diabetic nephropathy

1 reference

based on heuristic

inferred from title

author name string

Mao-Lu Tian

1

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Yan Shen

2

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Zhao-Lin Sun

3

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Yan Zha

4

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

publication date

11 April 2015

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

International Urology and Nephrology

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

47

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

815-822

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-0968-2

21 January 2018

Kidney disease and increased mortality risk in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-0968-2

21 January 2018

Standards of medical care in diabetes--2014

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-0968-2

21 January 2018

Regression of microalbuminuria in type 1 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-0968-2

21 January 2018

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-0968-2

21 January 2018

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-0968-2

21 January 2018

Combined angiotensin inhibition for the treatment of diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-0968-2

21 January 2018

The anti-inflammatory effects of the phosphodiesterase inhibitor pentoxifylline in the rat.

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-0968-2

21 January 2018

Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy.

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-0968-2

21 January 2018

Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-0968-2

21 January 2018

Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-0968-2

21 January 2018

Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-0968-2

21 January 2018

The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-0968-2

21 January 2018

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-0968-2

21 January 2018

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-0968-2

21 January 2018

Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-0968-2

21 January 2018

Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomized study

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-0968-2

21 January 2018

Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-0968-2

21 January 2018

Captopril and combination therapy of captopril and pentoxifylline in reducing proteinuria in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-0968-2

21 January 2018

Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-0968-2

21 January 2018

Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-0968-2

21 January 2018

Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial.

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-0968-2

21 January 2018

Pentoxifylline diminishes the oxidative damage to renal tissue induced by streptozotocin in the rat.

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-0968-2

21 January 2018

Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases.

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-0968-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11255-015-0968-2

21 January 2018

Pentoxifylline for diabetic kidney disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/25862237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of pentoxifylline for reduction of proteinuria in type II diabetic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/25862237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Initiation and progression of diabetic nephropathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/25862237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25862237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of intermittent claudication with pentoxifylline: a 12-month, randomized trial--walking distance and microcirculation

1 reference

https://pubmed.ncbi.nlm.nih.gov/25862237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25862237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Changes in diabetes-related complications in the United States, 1990-2010

1 reference

https://pubmed.ncbi.nlm.nih.gov/25862237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pentoxifylline suppression of tumor necrosis factor gene transcription

1 reference

https://pubmed.ncbi.nlm.nih.gov/25862237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11255-015-0968-2

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38415424&oldid=1758193814"